Deutsche Bank downgrades Novo Nordisk and the shares slip about 3%

Deutsche Bank downgraded Novo Nordisk on August 27, 2026, and cut its price target to 265 Danish kroner from 290 kroner, according to analyst Emmanuel Papadakis ^[1]. Shares fell as much as 2.9% on the news ^[1]. The bank pointed to a looming patent cliff, mixed second-quarter results, and doubts about whether Novo Nordisk can return to strong growth in 2027 ^[1].

A big part of the concern is Novo's thinning pipeline of new drugs. Ziltivekimab, an anti-inflammatory drug Novo had been developing, failed in a late-stage trial to reduce the risk of heart attack or stroke, and Deutsche Bank effectively removed it from near-term earnings expectations ^[1]. The development summary also points to a mixed record for CagriSema, Novo's combination obesity drug, as part of what has narrowed the company's visible pipeline; the sources reviewed here do not give specific trial numbers for CagriSema, so the exact nature of those results is not yet known from this reporting.

Not every analyst agrees the selloff is justified. Citi has kept a 'neutral' rating on Novo Nordisk, citing pricing pressure and rising competition in the GLP-1 market, but has also said the market's reaction to the ziltivekimab failure may be overdone given how little that drug contributed to Novo's overall valuation ^[1]. Novo Nordisk's Capital Markets Day is scheduled for September 21, 2026, in London, and investors are treating it as the moment management must lay out a clearer growth strategy ^[1].

The downgrade came even as Novo Nordisk had other news to point to. China's National Medical Products Administration accepted Novo's application to sell an oral tablet version of Wegovy, moving it into formal review ^[1]. JPMorgan analysts estimate China's GLP-1 weight-management market could grow to about 30 billion yuan, or roughly $4.1 billion, over the next five to seven years, up from 3 to 4 billion yuan today, as China's overweight and obese population is projected to exceed 65% of its population by 2030 ^[1].

Why it matters for patients

A stock downgrade does not change whether a drug is safe or available. It reflects investors' doubts about Novo Nordisk's future earnings, not a judgment on Wegovy or Ozempic's effectiveness for the people currently using them. Separately from the stock move, the FDA has already approved a higher-dose injectable version of semaglutide, Wegovy HD (7.2 mg), based on the STEP UP trial program, which showed 20.7% mean weight loss in participants with obesity and about 14.1% mean weight loss in those with obesity and type 2 diabetes ^[2]. Novo Nordisk expected to launch Wegovy HD in the US in April 2026 ^[2].

For patients, the practical stakes in a downgrade like this are indirect. If investors keep pushing Novo Nordisk to defend growth and margins, that pressure can shape decisions on drug pricing, manufacturing investment, and which pipeline programs get funded or dropped, including future dosing options or new indications. The ziltivekimab failure, for instance, was a cardiovascular-inflammation drug, not a currently marketed obesity or diabetes treatment, so its setback does not affect people already on Ozempic, Wegovy, or Rybelsus.

What happens next

Novo Nordisk's Capital Markets Day is set for September 21, 2026, in London, where management is expected to update long-term targets ^[1]. Full results from a trial testing semaglutide for Alzheimer's disease are expected around September 2026 ^[1]. China's review of the Wegovy tablet application will continue after the NMPA's formal acceptance, though a timeline for a decision is not given in the available reporting ^[1].